Four out of the 70 urinary peptides showing a statistically significant upregulation following treatment with GLP-1R agonists in T2DM patients originated from COL3A1 (n = 3) and COL1A2 (n = 1) (Table 2). Here, GLP1R is linked to type 2 diabetes mellitus.